Cardlytics, Inc. (CDLX) shares are progressing more than 26 percent on Monday morning trade announced that it has entered into a settlement agreement with Shareholder Representative Services LLC, or SRS, and successfully resolved all disputes related to the Bridg merger agreement and the earnout payments.
Further, Cardlytics expects to achieve positive adjusted EBITDA for the full year 2023.
Currently, shares are at $7.25, up 25.65 percent from the previous close of $5.77 on a volume of 3,565,672.
For comments and feedback: editorial@rttnews.com